ATLANTA -- Atlanta-based Vystar Corporation will introduce its revolutionary new latex named Vytex to manufacturers of latex products at the International Latex Conference to be held in Charlotte, N.C., July 26-27. Described as "the new safe latex," Vytex natural rubber latex is produced through a proprietary process that deactivates antigenic proteins in latex making it safe for use by persons who are allergenic-protein
sensitive.
A technical paper, A Novel Protein-Free Natural Rubber Latex: Properties and Applications, describing the research that created Vytex natural rubber latex and written by Vytex inventor, Vystar president and CEO Travis Honeycutt and Vystar executive vice president and COO William Doyle, will be presented at the conference.
"We are very excited to be included in this prestigious conference," Honeycutt said. "We believe that the introduction of Vytex natural rubber latex will ultimately be recognized as a pivotal event in the development of latex technologies."
Honeycutt went on to explain, "Our process gets protein levels down below ranges standard tests currently label as 'undetectable.' Importantly, Vytex natural rubber latex can replace traditional natural rubber latex in virtually any manufacturing environment," he said, adding, "all of these processes are employed prior to vulcanization of the natural latex rubber."
Doyle pointed out that the invention of Vytex natural rubber latex is particularly critical to the healthcare industry. "Recent focus groups validate the need for a natural rubber latex without the historic problem of allergenic proteins. Operating room nurses and surgeons have expressed dissatisfaction with synthetic substitutes and a desire for latex gloves that would be safe for patients and healthcare workers," Doyle said.
"The past two decades' accelerated use of protective gloves in the healthcare industry to protect against infectious diseases such as AIDS and SARS has escalated the problem. Today estimates put the number of healthcare workers affected by latex allergies as high as 17 percent," he said.
Noting that Vytex natural rubber latex has already garnered the interest of manufacturers across a broad range of product categories, Doyle said that plans to start Vytex natural rubber latex production are underway.
Vytex natural rubber latex is produced through a novel, patented method for the deactivation of the antigenic proteins (AP) in liquid natural rubber latex that involves the quasi-sequestration of these proteins. The Vytex scientific team has found that this method "denatures" the proteins by altering the stereochemistry of their structures, thus reducing the ability to generate an immune response.
Early results indicate that the deactivation method has no adverse effects on the physical and chemical properties of natural rubber latex as it is used in the manufacture of dipped products, and barrier properties may actually be slightly improved over untreated natural rubber latex. Studies are currently in progress to verify these claims.
Source: Vystar Corporation
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.
The Neglected Tropical Diseases You’ve Never Heard Of
February 27th 2024The 20 conditions, known as neglected tropical diseases (NTDs), are estimated to affect more than 1 billion people, yet many individuals have never heard of them. Heather Saunders, MPH, RN, CIC, discusses 5 of them and what is being done to prevent their spread.